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Hypomelanosis is a prevalent skin disorder in individuals with dark skin. 
Numerous inflammatory skin disorders cause hypomelanosis, even depigmenta-
tion. Its pathogenesis remains unknown, but it can be attributed to changes in 
melanin production in response to inflammation. The clinical manifestations, 
often including lesions with ill-defined borders limited to the site of inflammation, 
mostly appear in individuals with dark skin. The most important way to manage 
PIH is to effectively treat the underlying skin disorder that has led to it, however, 
medical therapy and phototherapy can be helpful, as well.
Keywords: PIH, hypomelanosis secondary to inflammation, depigmentation, 
pathogenesis, melanocytes
1. Introduction
Hypomelanosis is a prevalent skin disorder in dark-skinned Individuals. The 
numerous skin diseases that cause hypomelanosis include psoriasis, mycosis 
fungoides, sarcoidosis, pityriasis lichenoides chronica, lichen striatus, lupus ery-
thematosus and lichen sclerosus. Different clinical pictures of lesions and multiple 
factors in developing post-inflammatory hypopigmentation (PIH) constitute a 
diagnostic challenge for dermatologists.
1.1 Pathogenesis
Although many studies have addressed PIH, its exact etiology remains unknown 
and needs the assistance of cytologists. PIH is actually caused by a disorder in 
melanocyte-keratinocyte interactions. The release of inflammatory agents can 
be involved in the synthesis of melanin or transfer of melanin to keratinocytes, 
especially by inhibiting the transfer of melanin from melanocytes to keratinocytes. 
Melanocytes can respond by changing melanin production in response to posttrau-
matic stress and inflammation.
Individuals inherit chromatic tendency in the predominantly autosomal domi-
nant form. Hypopigmentation can develop as a result of damage to melanocytes, 
especially in patients with weak melanocytes. It is worth noting that melanocytes 
can be weak even in individuals with fair skin. Different factors control melanogen-
esis as a complex process that involves the synthesis, transfer and release of mela-
nin. PIH is mostly caused by the inhibition rather than destruction of melanocytes. 
Inflammation
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Moreover, severe inflammatory responses of the skin can cause melanocyte loss or 
death and thus pigmentation changes.
1.2 Clinical manifestations
The clinical manifestations, often including lesions with ill-defined borders 
limited to the site of inflammation, mostly emerge in individuals with dark skin, 
especially in those prone to hypopigmentation or even depigmentation. They are 
associated with diagnostic challenges, especially in children, as they can be associ-
ated with minor or asymptomatic variations.
The clinical features normally vary based on the primary skin lesions and the 
lesion margins are often blurred.
The rate of hypopigmentation varies with the age and severity of the cutane-
ous lesions and severity of the inflammation. Identifying the underlying cause of 
hypopigmentation can be difficult upon the patient admission, as inflammation of 
advanced lesions may decrease in severity or even gradually disappear (Figure 1). 
A complex description and frequent examinations are therefore required in these 
cases. Biopsy and histological examinations are also required in the absence of 
inflammatory symptoms.
1.3 Treatment
The most important treatment is to effectively treat the underlying skin disorder 
that has led to PIH because PIH usually improves over time.
UVB phototherapy and epidermal melanocyte transplantation can help treat 
completely-destroyed or depigmented melanocytes. Photo protection, apply 
broad spectrum (UVAUVB) SPF 30 or 50 and reapply every 2–4 hours self-
tanner (dihydroxyocetonc). Applying topical ironoxide (3%) can effectively 
protect the skin against blue visible light, especially in dark-skinned patients 
with PIH.
Figure 1. 
Psoriasis, showing multiple-well dermarcated hypopigmented lesions.
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2. Diseases of PIH
2.1 Pityriasis alba
2.1.1 Introduction
Pityriasis albais a prevalent benign but chronic and inflammatory dermatosis 
and a minor skin feature of atopic dermatitis that mostly emerges in 3 to 16-year-old 
individuals. Its prevalence is 1.9%–9.9% in children and up to 5%, especially when 
coupled with atopic dermatitis.
2.1.2 Pathogenesis
Different mechanisms can be considered for explaining the still-unknown 
etiology of pityriasis alba. A history of atopic dermatitis constitutes a pathogenic 
factor in pityriasis alba.
A Positive Relationship between health habits and pityriasis alba, frequent 
bathing and excessive washing may contribute to the lesion.
Nutritional factors and copper deficiency are also effective. Tyrosine in dermal 
cells involved in producing melanin is activated by copper. Pathological examina-
tions with electron microscopy and light microscopy showed decreases in the 
number and size of melanosomes in the affected skin [1].
2.1.3 Clinical manifestations
The eruptions usually appear as round or oval macules or patches with an indis-
tinct border with or without slight and often asymptomatic scales (Figure 2). The 
lesions normally become more visible in summer and may initially appear pink in 
Figure 2. 
Pityriasis alba: A common disfiguring hypomelanosis, which, as the name indicates, is a white area (alba) 




a way that the erythema subsides and turns white with powdery appearance and a 
pink border within a few weeks. With a size of 5–30 mm, the lesions mostly involve 
the face. Direct examination of scrapings with 10% KOH and slit-skin smear are 
respectively used to diagnose tinea versicolor and leprosy, and Wood’s lamp exami-
nations are performed for distinguishing vitiligo and the diseases associated with 
hypopigmentation.
It is mostly a cosmetic problem in persons with brown or black skin and commonly 
occurs on the face, as in this child. Among 200 patients with pityriasis alba, 90% 
ranged from 6–12 years of age. In young adults, PA quite often occurs on the arms  
and trunk [2].
2.1.4 Treatment
If pityriasis alba is left untreated, it can turn chronic and recurrent, although it 
self-heals in most cases after puberty. Topical steroids class V help reduce the lesion 
inflammation caused by pityriasis alba. Calcineurin inhibitors such as pimecrolimus 
cream1% and tacrolimus ointment 0.3% or 0.1% with anti-inflammatory properties 
can positively affect and activate tyrosinase and thus increase melanin synthesis [3]. 
Narrow-band UVB and excimer light or excimer laser treatment also yields proper 
responses through 5–10 treatments of 308 nm excimer laser.
2.2 Cutaneous lupus erythematosus
2.2.1 Introduction
Cutaneous lupus erythematosus is more prevalent in women with dark skin, 
especially in their fourth decade of life. One to five percent of the patients may 
progress to systemic lupus erythematosus.
2.2.2 Pathogenesis
Trauma and UVR may have been involved in the onset and exacerbation of 
symptoms in a person with a predisposed background. Photosensitivity is also 
observed in 50% of the patients. Histologic examinations can suggest lympho-
cytic interface dermatitis with basal layer degeneration (hydropic degeneration), 
keratinocyte apoptosis, basement membrane thickening (greatest in discoid lupus 
erythematosus), perivascular and periadnexal lymphohistiocytic infiltrate, follicu-
lar plugging, cutaneous mucinosis, epidermal atrophy, fibrosis, hypomelanosis and 
amelanosis, which are observed especially in the center of the lesions.
2.2.3 Clinical manifestations
As the most prevalent manifestations, sharply demarcated lesions in discoid 
lupus erythematosus (DLE) can be round, justifying the term “discoid”. The face 
and scalp constitute the most commonly affected sites.
DLE lesions are usually asymmetric and asymptomatic with a well-defined and 
elevated margin, which explains their red to violaceous color. These lesions often 
appear atrophic and hypopigmented or depigmented, especially in black individuals 
with prominent follicular plugs (Figure 3). Their hypopigmented center is often 
surrounded by a hyperpigmented margin.
Systemic lupus erythematosus can be assessed by performing a complete blood 
count, an erythrocyte sedimentation rate and an antinuclear antibody test.
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2.2.4 Treatment
Initial treatment options include topical steroids, intralesional steroids, anti-
malarial medications such as Hydroxychloroquine, and acitretin. High-potency 
corticosteroids are recommended for the facial lesions.
Intralesional triamcinolone, commonly at a concentration of 4 to 5 mg/ml, can 
be very effective especially in active discoid lesions.
Reports suggest the successful application of new topical immunomodulators 
such as tacrolimus to cutaneous lesions.
2.3 Systemic sclerosis (scleroderma)
2.3.1 Introduction
As a collagen vascular disease with cutaneous fibrosis as its skin manifestation, 
systemic sclerosis causes skin tightening and pigmentary changes. The incidence 
and prevalence of scleroderma are respectively below two per million and 25 per 
million [4, 5].
2.3.2 Pathogenesis
Abnormal immune responses, vascular dysfunction and activation of connective 
tissue cells have been reported in genetically-predisposed individuals. Different 
environmental and occupational factors such as silica and [6]. organic solvents can 
be involved.
Electron microscopy shows depigmentation, loss of melanocytes and degenera-
tive changes.
Figure 3. 
Discoid lupus erythematosus; there are well-defined, erythematous, scaling lesions with a pigmented margin 




The clinical patterns of the disease include limited cutaneous systemic sclerosis, 
which is limited to distal limbs, reaches up to the knees and elbows and usually 
involves the face.
The patients may present only with fibrosis of the fingers. The other pattern, 
diffuse cutaneous systemic sclerosis, involves the trunk in its early stages and 
facial involvement is uncommon. This type is often associated with more systemic 
involvements and a worse prognosis.
Systemic sclerosis can cause diffuse hyperpigmentation that is exacerbated 
in sun-exposed areas, a specific manifestation of leukoderma. A combination of 
hypomelanosis and hypermelanosis can be present in the sclerotic and non-sclerotic 
skin areas of patients with systemic sclerosis, especially on their hands. Leukoderma 
emerging as complete depigmentation can be comorbid with supravenous hyper-
pigmentation and perifollicular macules (Figure 4). This type of leukoderma can 
suggest suspected systemic scleroderma.
Histological examinations with an electron microscope shows complete or 
partial loss of melanocyte pigmentation coupled with degenerative  
changes.
It is actually a collagen vascular disease with some degree of cutaneous fibrosis 
that causes skin tightening.
2.3.4 Treatment
Topical and intralesional steroids are recommended for the inflammatory stages. 
Topical tacrolimus, calcipotriol and imiquimod have been also used. Combination 
therapies used in the absence of responses include calcipotriol and betamethasone 
or imiquimod or low dose PUVA alone or with calcipotriol.
Figure 4. 
“Salt and pepper” sign Leukoderma with the retention of perifollicular pigmentation in a patient with 
systemic sclerosis.
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2.4 Hypopigmented mycosis fungoides (HMF)
2.4.1 Introduction
HMF is a variant of early MF, which is more prevalent in black individuals. HMF 
mostly affects ages of 30–40 years, although this type can involve 25–50% of chil-
dren and adolescents. In fact, it is a prevalent type of MF in children. As a prevalent 
condition in the Middle East, HMF can be misdiagnosed as pityriasis alba or tinea 
versicolor in children. A study reported HMF in18 out of 34 subjects and 29 out of 
50 adolescents and children [7].
2.4.2 Pathogenesis
Mycosis fungoides is a cutaneous T-cell lymphoma with a major phenotype of 
C8+T cells and a pathogenic similarity to vitiligo. Given the absence of clinically 
hypopigmented lesions in the majority of patients with mycosis fungoides and T 
cells, presence of cytotoxic T cell phenotypesis not adequate for inducing hypopig-
mentation. Although electron microscopy shows melanosome degradation in 
melanocytes and keratinocytes, the large number of normal melanosomes found in 
melanocytes suggests a defect in melanosome transfer.
2.4.3 Clinical manifestations
Patients with mycosis fungoides May present with hypopigmented patches and 
plaques, usually associated with mild erythema and pruritus (Figure 5). The lesions 
are distributed more in the trunk and proximal areas of the limbs, especially in the 
non-exposed areas. Closer examinations show erythematous lesions.
Figure 5. 




Repigmentation following treatments can be a sign of their effectiveness. 
Despite being the only manifestation of conventional mycosis fungoides, HMF is 
better in terms of its prognosis [8].
One year of treatment with a combination of steroids and tacrolimus, twice a 
week, was reported to significantly improve hypopigmented patches and cause no 




Hypopigmented sarcoidosis is a multisystem granulomatous disease that 
affects organs such as the lungs, eyes and skin as well as lymph nodes. The exact 
cause of hypopigmentation in sarcoidosis is unknown. Cutaneous manifestations 
have been reported in one- quarter to one-third of patients with systemic sarcoid-
osis. The prevalence of the lesions with different morphologies has been reported 
as high as 60% in black individuals. The prevalence is also twice in females than 
in males.
2.5.2 Pathogenesis
Sarcoidosis can be caused by autoimmune reactions or genetic processes given 
the existing racial and ethnic differences. HLA haplotype diversity patterns can 
explain different manifestations between different races. This disorder is histopath-
ologically categorized as a granulomatous disease given the non-caseating granulo-
mas found in the dermis. Electron microscopy also shows vacuolated melanocytes 
and decreases in the number of melanosomes in keratinocytes. Granulomas mainly 
include epithelioid cells and occasionally giant cells, with lymphocytic infiltration 
around granulomasin the absence of caseous necrosis.
2.5.3 Clinical manifestations
The most prevalent skin manifestations of sarcoidosis include small erythem-
atous-violaceous papules 3–5 mm. Sarcoidosis often initiates in an acute state and 
then becomes chronic. With a peripheral scaly marginand a hypopigmented center 
(Figure 6), the annular lesions are usually limited to the head and neck with a 
poor prognosis. A rare cutaneous form with patches or plaques usually appearing 
1–10 mm in size mainly involves the trunk and face. Erythematous papules in the 
center of the patches resemble a fried egg [10].
The patients are often asymptomatic and usually diagnosed through radiological 
examinations. A skin biopsy and pathological examinations may also be ultimately 
required.
2.5.4 Treatment
Although acute sarcoidosis is a self-healing conditions, cutaneous sarcoidosis 
with systemic involvement can be treated with 1 mg/kg/day of prednisolone as an 
oral steroid to cleanse the skin lesions. The localized skin manifestations can be 
treated only with topical steroids or intralesional injections. Anti-TNF biologic 
medications can be used as alternatives to steroids, especially when steroids are 
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contraindicated. Hypopigmented cutaneous sarcoidosis is responsive to minocycline 
[11] and can be treated with 8-methoxypsoralen [12] and long-wave ultraviolet light.
2.6 Lichen Striatus
2.6.1 Introduction
Lichen striatus is a benign self-limiting dermatosis with an unknown etiology. It 
is more prevalent in children than in other age groups, it is acquired and unilaterally 
occurs along the lines of blaschko. Although the lesions are often transient, they 
may be of a prolonged form.
Lichen striatus is associated with vitiligo or atopic dermatitis. It mainly affects 
children at an age of 3.5 years, although it may occur in children of 4 months to 
10 years of age.
2.6.2 Clinical manifestations
Lichen striatus usually manifests itself as smooth and scaly or hypopigmented 
flat-topped papules, which are 2-4 mm in size and initially inflammatory  
(Figure 7). The lesions appear as continuous or interrupted flat papules along the 
lines of blaschko within 2–3 weeks. The eruptions, being mainly distributed in the 
limbs, especially the lower limbs, normally leave a long-lasting hypopigmentation 
in 50% of the cases. According to recent studies in India, lichen striatus causes 
hypopigmentation in approximately 1.7% of the patients [13].
2.6.3 Treatment
No treatments are normally required given the benign and self-limiting nature 
of the disease. Tacrolimus ointment has been found to speed up the relief and cause 
complete healing without skin sequelae.
Figure 6. 
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3. Conclusion
Numerous inflammatory skin diseases can cause pigmentation disorders, which 
suggests that despite multiple inflammatory disease of skin, ultimately through the 
activation of inflammatory agents located in the skin, such as T cells, cytokines and 
other inflammatory cells that lead to disregulation of melanogenesis system.
However, the exact mechanism of PIH is not known and further studies are 
needed. Despite advance in treating the cause of the hypomelanosis, but PIH is still 
a challenge for dermatologists. Appropriate treatment for PIH is to identify the 
underlying cause and treat it, with applying symptomatic therapy.
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Figure 7. 
Lichen striatus: Linear streaks on the leg alongthe lines of Blaschko, comparing numerous small, flat-topped 
tan (hypopigmented) papules.
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